Glucosalino Hiposódico

Glucosalino Hiposódico is an intravenous solution that combines sodium chloride and glucose monohydrate in a balanced formulation designed for fluid and electrolyte replacement. The product is supplied as a sterile solution for IV administration and is marketed in the European Union. It is prescribed by healthcare professionals for patients who require controlled sodium and glucose delivery to support extracellular fluid volume and metabolic needs in clinical practice.

Glucosalino Hiposódico is indicated for several clinical situations where fluid, electrolyte, or glucose supplementation is required. - Replacement of extracellular fluid losses due to dehydration, burns, or gastrointestinal fluid loss. - Maintenance of sodium and chloride balance during peri‑operative or intensive‑care management. - Treatment of mild to moderate hypoglycemia when combined with dextrose therapy. - Support of patients receiving parenteral nutrition who need additional sodium and glucose. - Rehydration of patients with electrolyte disturbances such as hyponatremia or hypochloremia. - Use in emergency or trauma settings to provide rapid intravascular volume expansion and osmotic support.

Adverse reactions to Glucosalino Hiposódico are generally related to the infusion of electrolytes and glucose and may vary in frequency and severity.

Common: - Mild infusion site irritation or erythema. - Transient hypernatremia or hyperglycemia that resolves with monitoring. - Nausea or mild abdominal discomfort. - Transient increase in blood glucose level. - Mild headache or dizziness during rapid infusion.

Serious: - Severe electrolyte imbalance such as hypernatremia, hyponatremia, or hyperchloremia. - Allergic reaction including urticaria, bronchospasm, or anaphylaxis. - Volume overload leading to pulmonary edema. - Metabolic acidosis in patients with impaired glucose metabolism. - Cardiac arrhythmias associated with rapid shifts in serum sodium. - Renal impairment exacerbated by high sodium load.

When prescribing Glucosalino Hiposódico, clinicians should evaluate patient-specific factors and monitor relevant parameters to minimize risks. - Assess baseline serum electrolytes and glucose before initiation. - Adjust infusion rate in patients with cardiac or renal insufficiency to avoid volume overload. - Use caution in individuals with known hypersensitivity to sodium chloride or glucose solutions. - Monitor blood pressure and fluid balance during and after administration. - Avoid rapid bolus administration unless clinically indicated for emergency resuscitation. - Re‑evaluate therapy regularly in neonates, elderly, or critically ill patients.

Glucosalino Hiposódico may interact with other intravenous therapies or medications that affect fluid, electrolyte, or glucose balance.

Avoid: - Co‑administration with hypertonic saline solutions, which can cause excessive sodium load. - Simultaneous infusion of high‑dose dextrose preparations that may lead to severe hyperglycemia. - Concurrent use with potassium chloride solutions, which may cause hyperkalemia when combined with sodium load.

Use with caution: - Loop diuretics, as they can exacerbate electrolyte shifts during therapy. - ACE inhibitors or ARBs, which may alter renal handling of sodium and potassium. - Vasopressors, because rapid volume changes can affect hemodynamic response. - Insulin therapy, as glucose infusion can modify insulin requirements and risk of hypoglycemia.